We report the population pharmacokinetic (PK) and exposure-response analyses of a novel subcutaneous formulation of daratumumab (DARA) using data from 3 DARA subcutaneous monotherapy studies (PAVO Part 2, MMY1008, COLUMBA) and 1 combination therapy study (PLEIADES). Results were based on 5159 PK samples from 742 patients (DARA 1800 mg subcutaneously, n = 487 [monotherapy, n = 288; combination therapy, n = 199]; DARA 16 mg/kg intravenously, n = 255 [all monotherapy, in COLUMBA]; age, 33-92 years; weight, 28.6-147.6 kg). Subcutaneous and intravenous DARA monotherapies were administered once every week for cycles 1-2, once every 2 weeks for cycles 3-6, and once every 4 weeks thereafter (1 cycle is 28 days). The subcutaneous DARA combination th...
Background: Standard of care for SMM includes active monitoring until progression to multiple myelom...
Objective To systematically evaluate the efficacy and safety of combination regimens containing dara...
Daratumumab, a human CD38 IgG1κ monoclonal antibody, has activity as monotherapy in multiple myeloma...
We report the population pharmacokinetic (PK) and exposure-response analyses of a novel subcutaneous...
Aim: A population pharmacokinetic (PPK) model was developed to characterize pharmacokinetics (PK) of...
Daratumumab, a human monoclonal antibody targeting CD38, is approved as monotherapy and in combinati...
Introduction: Daratumumab, a human immunoglobulin Gκ monoclonal antibody targeting CD38, is approved...
New therapeutic strategies are urgently needed to improve clinical outcomes in patients with multipl...
In the primary analysis of the phase 3 COLUMBA study, daratumumab by subcutaneous administration (DA...
Background: Intravenous daratumumab for treatment of patients with multiple myeloma involves a lengt...
In the primary analysis of the phase III COLUMBA study, daratumumab by subcutaneous administration (...
© 2020 The Authors. Daratumumab is a CD38-targeting monoclonal antibody approved for intravenous (IV...
Current guidelines for smoldering multiple myeloma (SMM) recommend active monitoring until the onset...
Background: Daratumumab, an anti-CD38 monoclonal antibody, is used for treatment of multiple myeloma...
Patients with multiple myeloma (MM) are typically of an advanced age and may have significant co-exi...
Background: Standard of care for SMM includes active monitoring until progression to multiple myelom...
Objective To systematically evaluate the efficacy and safety of combination regimens containing dara...
Daratumumab, a human CD38 IgG1κ monoclonal antibody, has activity as monotherapy in multiple myeloma...
We report the population pharmacokinetic (PK) and exposure-response analyses of a novel subcutaneous...
Aim: A population pharmacokinetic (PPK) model was developed to characterize pharmacokinetics (PK) of...
Daratumumab, a human monoclonal antibody targeting CD38, is approved as monotherapy and in combinati...
Introduction: Daratumumab, a human immunoglobulin Gκ monoclonal antibody targeting CD38, is approved...
New therapeutic strategies are urgently needed to improve clinical outcomes in patients with multipl...
In the primary analysis of the phase 3 COLUMBA study, daratumumab by subcutaneous administration (DA...
Background: Intravenous daratumumab for treatment of patients with multiple myeloma involves a lengt...
In the primary analysis of the phase III COLUMBA study, daratumumab by subcutaneous administration (...
© 2020 The Authors. Daratumumab is a CD38-targeting monoclonal antibody approved for intravenous (IV...
Current guidelines for smoldering multiple myeloma (SMM) recommend active monitoring until the onset...
Background: Daratumumab, an anti-CD38 monoclonal antibody, is used for treatment of multiple myeloma...
Patients with multiple myeloma (MM) are typically of an advanced age and may have significant co-exi...
Background: Standard of care for SMM includes active monitoring until progression to multiple myelom...
Objective To systematically evaluate the efficacy and safety of combination regimens containing dara...
Daratumumab, a human CD38 IgG1κ monoclonal antibody, has activity as monotherapy in multiple myeloma...